AU2021336300A1 - LZK-targeting degraders and methods of use - Google Patents

LZK-targeting degraders and methods of use Download PDF

Info

Publication number
AU2021336300A1
AU2021336300A1 AU2021336300A AU2021336300A AU2021336300A1 AU 2021336300 A1 AU2021336300 A1 AU 2021336300A1 AU 2021336300 A AU2021336300 A AU 2021336300A AU 2021336300 A AU2021336300 A AU 2021336300A AU 2021336300 A1 AU2021336300 A1 AU 2021336300A1
Authority
AU
Australia
Prior art keywords
compound
lzk
substituted
unsubstituted
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021336300A
Other languages
English (en)
Inventor
Knickole L. BERGMAN
John F. BROGNARD
Amy L. FUNK
Carolyn W. HITKO
Eric Lindberg
Katherine M. NYSWANER
Venkatareddy SABBASANI
Rolf E. Swenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2021336300A1 publication Critical patent/AU2021336300A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021336300A 2020-09-02 2021-09-01 LZK-targeting degraders and methods of use Pending AU2021336300A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073835P 2020-09-02 2020-09-02
US63/073,835 2020-09-02
PCT/US2021/048600 WO2022051326A1 (en) 2020-09-02 2021-09-01 Lzk‑targeting degraders and methods of use

Publications (1)

Publication Number Publication Date
AU2021336300A1 true AU2021336300A1 (en) 2023-03-16

Family

ID=78087503

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021336300A Pending AU2021336300A1 (en) 2020-09-02 2021-09-01 LZK-targeting degraders and methods of use

Country Status (6)

Country Link
US (1) US20240190838A1 (https=)
EP (1) EP4208455A1 (https=)
JP (1) JP2023539754A (https=)
AU (1) AU2021336300A1 (https=)
CA (1) CA3193736A1 (https=)
WO (1) WO2022051326A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188848A1 (en) * 2024-03-06 2025-09-12 Uereka Biosciences, Inc. Lzk inhibitors
CN118652241A (zh) * 2024-05-29 2024-09-17 浙江工业大学 mTOR蛋白靶向降解嵌合体及其制备方法与应用
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB201506871D0 (en) * 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018044808A1 (en) 2016-08-29 2018-03-08 Board Of Regents, University Of Texas System Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease
KR20190087622A (ko) * 2016-12-08 2019-07-24 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제
US10806737B2 (en) * 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
WO2019195609A2 (en) * 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
US11560366B2 (en) * 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
WO2021141662A1 (en) * 2020-01-10 2021-07-15 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (protacs) with functional handles and uses thereof

Also Published As

Publication number Publication date
CA3193736A1 (en) 2022-03-10
WO2022051326A1 (en) 2022-03-10
EP4208455A1 (en) 2023-07-12
US20240190838A1 (en) 2024-06-13
JP2023539754A (ja) 2023-09-19

Similar Documents

Publication Publication Date Title
US20240190838A1 (en) Lzk-targeting degraders and methods of use
AU2018219292B2 (en) Tunable endogenous protein degradation with heterobifunctional compounds
JP6473330B2 (ja) ＲａｌＧＴＰアーゼを標的とする抗がん化合物及びその使用方法
US9943506B2 (en) BCL6 inhibitors as anticancer agents
JP7850460B2 (ja) ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用
Zhou et al. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D
US20250032489A1 (en) Mixed lineage kinase inhibitors and methods of use
JP7508449B2 (ja) Ｕｓｐ７の阻害
JP2020105195A (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
Sanchez-Arias et al. Impact of scaffold exploration on novel dual-acting histone deacetylases and phosphodiesterase 5 inhibitors for the treatment of Alzheimer’s disease
Krummenacher et al. Discovery of orally available and brain penetrant AEP inhibitors
US10273208B2 (en) Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods
US20150246946A1 (en) Peptides and methods for treating cancer
WO2023203174A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
Ge et al. Discovery of SY-589, a Highly Potent and Orally Bioavailable Polθ Helicase Inhibitor for the Treatment of HR-Deficient Tumors
US20250304585A1 (en) Sulfamate based covalent ligand-directed release (coldr) compounds
WO2026025042A1 (en) P53 targeting compounds and uses thereof
Jones et al. Activity-Based Proteomics Discovery of Deubiquitinating Enzyme Inhibitors with Immunomodulatory Activity
WO2024249959A1 (en) Compositions reducing the expression or activity of c1 galt1 for treating ewing sarcoma
WO2025151850A9 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3
JP2020508969A (ja) オーロラａキナーゼ選択的阻害剤
WO2025101571A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders